mirococept

Mirococept is a recombinant protein-based complement inhibitor designed to regulate excessive complement activation at cell surfaces during inflammation. It consists of the first three short consensus domains of human complement receptor 1 (CR1), modified with a membrane-targeting amphiphilic peptide to enhance its affinity for cell membranes[1][6]. Mirococept acts by inhibiting C3/C5 convertases in both the classical and alternative pathways of the complement system, leading to dissociation and inactivation of C3b from these convertases and thereby blocking generation of activated C3 as well as release of inflammatory mediators C3a and C5a[1][8]. The drug was developed primarily for use in conditions involving ischemia-reperfusion injury (IRI), such as delayed graft function after kidney transplantation, but has also been investigated for rheumatoid arthritis, transplant rejection, shock, inflammation, and inflammatory bowel diseases[2][4][5]. Mirococept can be administered ex vivo directly to donor organs prior to transplantation[4][5], aiming to reduce post-transplant complications related to IRI.